Skip to content
Lartruvo(olaratumab)
Lartruvo (olaratumab) is an antibody pharmaceutical. Olaratumab was first approved as Lartruvo on 2016-10-19. It is used to treat sarcoma in the USA. It has been approved in Europe to treat sarcoma. The pharmaceutical is active against platelet-derived growth factor receptor alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Olaratumab
Tradename
Proper name
Company
Number
Date
Products
LartruvoolaratumabEli LillyN-761038 DISCN2016-10-19
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
sarcoma—D012509—
Agency Specific
FDA
EMA
Expiration
Code
olaratumab, Lartruvo, Eli Lilly and Company
2120-02-25Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX10: Olaratumab
HCPCS
Code
Description
J9285
Injection, olaratumab, 10 mg
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509731—110
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C61—1———1
Pancreatic neoplasmsD010190EFO_0003860C2511———1
GlioblastomaD005909EFO_0000515—1———1
Non-small-cell lung carcinomaD002289—1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C803————3
Neoplasm metastasisD009362EFO_00097082————2
LeiomyosarcomaD0078901————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOLARATUMAB
INNolaratumab
Description
Olaratumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1024603-93-7
RxCUI1855735
ChEMBL IDCHEMBL1743049
ChEBI ID—
PubChem CID—
DrugBankDB06043
UNII IDTT6HN20MVF (ChemIDplus, GSRS)
Target
Agency Approved
PDGFRA
PDGFRA
Organism
Homo sapiens
Gene name
PDGFRA
Gene synonyms
PDGFR2, RHEPDGFRA
NCBI Gene ID
5156
Protein name
platelet-derived growth factor receptor alpha
Protein synonyms
Alpha platelet-derived growth factor receptor, Alpha-type platelet-derived growth factor receptor, CD140 antigen-like family member A, CD140a, CD140a antigen, PDGF-R-alpha, PDGFR-2, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, platelet-derived growth factor receptor, alpha polypeptide
Uniprot ID
Q9UD28
Mouse ortholog
Pdgfra (18595)
platelet-derived growth factor receptor alpha (Q8C4N3)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 678 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
514 adverse events reported
View more details